Iowa State Bank Acquires 422 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Iowa State Bank grew its position in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 1.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,318 shares of the biopharmaceutical company’s stock after purchasing an additional 422 shares during the period. Iowa State Bank’s holdings in Gilead Sciences were worth $3,266,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PCA Investment Advisory Services Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $25,000. Tompkins Financial Corp lifted its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. OFI Invest Asset Management acquired a new position in Gilead Sciences during the 3rd quarter worth about $26,000. Fortitude Family Office LLC acquired a new position in Gilead Sciences during the 4th quarter worth about $29,000. Finally, Union Savings Bank acquired a new position in Gilead Sciences during the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total transaction of $702,465.66. Following the completion of the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the sale, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,242 shares of company stock valued at $1,423,646. 0.21% of the stock is owned by insiders.

Analyst Ratings Changes

GILD has been the topic of several research reports. Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Cantor Fitzgerald lowered their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $85.36.

Check Out Our Latest Analysis on Gilead Sciences

Gilead Sciences Stock Down 1.1 %

NASDAQ:GILD traded down $0.79 during trading hours on Tuesday, reaching $72.09. 6,138,241 shares of the stock were exchanged, compared to its average volume of 7,529,001. Gilead Sciences, Inc. has a twelve month low of $71.37 and a twelve month high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm has a 50 day moving average of $74.46 and a 200 day moving average of $77.20. The stock has a market cap of $89.76 billion, a PE ratio of 16.20, a PEG ratio of 0.93 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILDGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $1.67 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is presently 68.44%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.